- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05951140
Personalised Nutrition for Healthy Living (PROTEIN)
Personalised Nutrition for Healthy Living: PROTEIN
The topic of diet and physical activity are of great importance in the treatment of T2D. In the daily routine of a practice or clinic, a doctor has an average of eight minutes per patient, leaving little time for lifestyle issues (Irving et al. 2017). An individualised procedure requires more time and therefore more resources. Currently, an app can be programmed with evidence-based information so that it provides appropriate personalised behavioural recommendations via machine learning. The user gets direct feedback and can make a behavioural change himself. On the one hand, this approach allows better use of doctor-patient time and, on the other hand, the patient learns through positive reinforcement in such a way that his or her behaviour change is supported and reinforced in the longer term and potentially sustainably.
The aim of this intervention pilot study within the scope of the EU-Horizon 2020 project is to investigate lifestyle support through a mobile app and wearables to improve lifestyle (personalised nutrition) and important metabolic outcomes in patients with type 2 diabetes or prediabetes. In addition, exploratory genetic and microbiome data will be explored to answer the question of personalisation of the recommendations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An inadequate diet and increasing sedentary lifestyle are major contributors to the rise of non-communicable diseases. Individualized recommendations can lead to a healthier lifestyle. The scientific evidence of the effectiveness of health apps offering personalized recommendations is limited.
The aim of this intervention pilot study within the scope of the EU-Horizon 2020 project is to investigate lifestyle support through a mobile app and wearables to improve lifestyle (personalised nutrition) and important metabolic outcomes in patients with type 2 diabetes or prediabetes. The Investigators want to asess whether the use of this mobile application that incorporates information of wearables (continuous glucose monitoring and fitness tracker), improves lifestyle and metabolic outcomes in patients with type 2 diabetes (T2D) or prediabetes. Our primary outcome is to improve time in range (TIR) by 5%.
It is a prospective randomized control pilot trial with an intervention period of 12 weeks. Participants will use the Protein app, a continuous glucose monitoring system (CGM) and an activity tracker to collect real world data to enable personalisation.
In order to identify the effect of the PROTEIN-Application, 300 participants with T2DM or prediabetes will be randomly allocated into two groups: the (1) start-group or the (2) wait-group. The start-group will use an activity tracker, a CGM and the PROTEIN app for 12 weeks followed by a six-week period without the app, but they will use the wearables. The wait-group will use an activity tracker and a CGM, but not the PROTEIN app for six weeks followed by a period of 12 weeks using the PROTEIN app. This study design allowed us to have a control group within the whole cohort and clearly see the influence of the PROTEIN app.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12203
- Charité Univesitätsmedizin Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years of age
- Diabetes Type 2 or Prediabetes
- BMI: 20-kg kg/m2
- Android Smart Phone/ Tablet use
- In good physical health
- Able to provide written informed consent
Exclusion Criteria:
- Severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
- Active or recent relevant cancer
- Currently receiving treatment with Insulin
- People with disordered eating (such as anorexia nervosa etc.)
- Those who are not be able to provide written consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Start-Group
The Start-Group starts with the Protein-Application and wereables for 3 Months and afterwards uses only wereables for 6 Weeks.
|
Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support.
Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application.
(2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
|
Experimental: Wait-Group
The Wait-Group starts with 6 Weeks of using only wereables and afterwards adds the usage of the Protein-Application.
|
Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support.
Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application.
(2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of Time In Range (TIR) by 5%
Time Frame: 12 Weeks
|
Our primary objective is to increase the time in range (TIR) of the study participants by 5%
|
12 Weeks
|
Improve eating behavior towards healthier choices
Time Frame: 12 Weeks
|
Improve eating behaviour towards healthier choices during the intervention time
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to dietary recommendations of the app
Time Frame: 12 Weeks
|
Adherence to dietary recommendations of the PROTEIN-App
|
12 Weeks
|
Improvement of glycaemic metabolism
Time Frame: 12 Weeks
|
Fasting glucose, HbA1c, HOMA-IR
|
12 Weeks
|
Reduction in sedentary time
Time Frame: 12 Weeks
|
Reduction in sedentary time, defined as: Activity time through fitness trackers or increase in physical activity or increase in steps per day
|
12 Weeks
|
Aproximation of the energy intake
Time Frame: 12 Weeks
|
Approximation of the energy intake (calorie intake and distribution of macronutrients) towards the agreed goals
|
12 Weeks
|
Measurable change in the faecal microbiome
Time Frame: 12 Weeks
|
Measurable change in the faecal microbiome by extraction of DNA and its analysis to identify the relevant species of bacteria
|
12 Weeks
|
Calculation of the Polygenic Risk Score
Time Frame: 12 Weeks
|
Calculation of the Polygenic Risk Score by Isolation of DNA from whole blood
|
12 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Lazaros Gymnopoulos, Dr, Information Technologies Institute, Centre for Research and Technology Hellas
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROTEIN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Usage of the PROTEIN-Application
-
Vilnius UniversityCompletedMetabolic SyndromeLithuania
-
FH Campus Wien, University of Applied SciencesCompletedDevelopmental Delay in Fine Motor Function (Disorder)Austria
-
Bayero University Kano, NigeriaCompleted
-
American British Cowdray Medical CenterUnknown
-
Faculdade de Ciências Médicas da Santa Casa de...Completed
-
Meir Medical CenterRecruitingQuality of Life | Food AllergyIsrael
-
University Hospital, Strasbourg, FranceUnknown
-
Navy General Hospital, BeijingNot yet recruitingVenous Thromboembolism | Clinical Decision Support Systems | Digital Health
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKRecruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of ExposureUnited Kingdom